Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsFor men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.
Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.
Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.
1.
Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025
2.
The September 2018 issue of Medical Bulletin.
3.
US to Loosen Marijuana Rules in Major Shift for $47 Billion Industry
4.
For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.
5.
CAR-T Induces Deep, Durable Remission in Smoldering Myeloma
1.
Tumor Microenvironment Reprogramming Through Stromal Modulation
2.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
3.
AI and Optical Advances: Evolving Blood Cell Morphology Observation in Hematology
4.
Advanced Advances in Oncology for Healthcare Excellence
5.
Harnessing Cuproptosis: A Novel Nanomedicine Strategy for Triple-Negative Breast Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
5.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge